BRAINBox Solutions Enrolls 1000th Patient in Pivotal, HeadSMART II Clinical Study of BRAINBox TBI Concussion Diagnostic and Prognostic Test

RICHMOND, VA. – BRAINBox Solutions today announced that the company  has enrolled the 1,000th patient in the pivotal, HeadSMART II study of its concussion diagnostic  and prognostic test, BRAINBox TBI. The multi-national, multi-site, trial is designed to  support an application for regulatory clearance by the U.S. FDA.  

“We are developing the BRAINBox TBI (Traumatic Brain Injury) test as the first objective test to aid in  the diagnosis of concussion and to provide an assessment of the risk of post-concussive symptoms,”  said Donna Edmonds, BRAINBox Solutions’ CEO. “We are now in the home stretch of this very  important study for the field. We believe the test has great potential to change clinical practice in the  diagnosis and management of concussion and will define for the first time, objective diagnostic  criteria for this condition, termed Acute Traumatic Encephalopathy (ATE). As such, the trial has been  rigorously designed in collaboration with leading experts in traumatic brain injury and emergency  medicine. The study evaluates patients in multiple settings and includes state of the art expert  adjudication panels.”  

She added that the current study is being conducted in adults (18 years old or older). A separate  National Institutes of Health-supported, multi-center study in geriatric subjects is expected to begin enrollment in late 2022 to establish a geriatric specific test for diagnosis and prognosis. Additionally,  the company is engaged a Pilot Study for a Pediatric Test for individuals under the age of 18, aimed at  the same claims as the adult study. 

The BRAINBox TBI multi-modal test combines clinical data, neurocognitive testing, symptom reporting  and blood-based biomarkers, with proprietary AI algorithms to generate an objective score for  diagnosis up to 96 hours from the time of injury. In addition, a prognosis report is generated, providing  the likelihood of injury-related symptoms occurring at 30 days and up to three months after the event.  The clinical study sites were selected to reflect real world practice and include Level I Trauma Centers, Emergency Departments and Urgent Care settings in systems and community-based hospitals.  

The HeadSMART II study’s primary endpoints include ATE diagnosis, as determined by the BRAINBox  TBI test, compared with the Gold Standard diagnosis and the test’s ability to predict persistent  symptoms up to 90 days after an ATE diagnosis. 

1000th Patient Enrolled Release, P. 2 

The Gold Standard for diagnosis is determined by an adjudication committee of clinical experts blinded to the test results. Two randomly selected experts each make a diagnostic determination  based on evaluation of the clinical information, including imaging and neurological assessments. If  there is discordance, a third expert performs an independent review and serves as the tie breaker. There is a similar expert adjudication process for neuroimaging data from participants who receive a head CT scan or MRI as part of standard of care. 

Adjudicated TBI patients are stratified as having high or low risk for post-concussive symptoms in each  symptom category, based on biomarker and neurocognitive testing. 

The design and oversight of the study is being conducted by leading experts in emergency medicine  and neurotrauma, including: W. Franklin Peacock MD FACEP, Principal Investigator, and Professor of  Emergency Medicine and Vice Chair for Research in the Department of Emergency Medicine at Baylor  College of Medicine; Damon Kuehl, MD, Vice Chair for Research in the Department of Emergency  Medicine for Carilion Clinic and Vice Chair of the Virginia Tech Carilion School of Medicine’s  Department of Emergency Medicine; and Ramon Diaz-Arrastia, MD, PhD, Professor of Neurology,  Director, Clinical TBI Research Center, University of Pennsylvania, Perelman School of Medicine, all of  whom are enrolling subjects in the study. Drs. Peacock, Kuehl and Diaz-Arrastia, also serve on the  BRAINBox Solutions Scientific Advisory Board (SAB). 

Additional SAB members who have been active in the study design and oversight are SAB Chairman, David Okonkwo MD PhD, Professor at University of Pittsburg Medical Center and Director,  Neurotrauma Clinical Trials Center, Director, Scoliosis and Spinal Deformity Program and Special  Advisor, UPMC Enterprises; and Alan Wu, Professor Laboratory Medicine, Chief, Clinical Chemistry  Laboratory, SFGH, and Chief, Clinical Pharmacogenomics Laboratory, UCSF. 

Additional information on the clinical trial can be found here at The HeadSMART II  study protocol was published in December, 2021 in Frontiers in Neurology

Read more here.

Recent News


Mason leads planning study to position Northern Virginia as a premier location for the life science industry

During the past several years, industry demand for a skilled life science workforce has been surging. In Virginia, while there are currently shortages in almost all health-related professions, little is known about whether there is an adequate supply of life science workers to meet the needs of employers. Now George Mason University is working toward


California invests $50M to partner with Civica Rx on insulin manufacturing

California Gov. Gavin Newsom has announced a new contract with nonprofit drugmaker Civica Rx, a move that brings the state one step closer to creating its own line of insulin to bring down the cost of the drug. Once the medicines are approved by the Food and Drug Administration, Newsom said at a press conference


RAMP Welcomes 5 Startups into Spring 2023 Cohort

From designing battery electric spotter tractors to developing individualized neuro-oncology treatments for aggressive gliomas, the five companies accepted into RAMP’s Spring 2023 Cohort span the gamut of technology, health science and life science innovation. “We are thrilled to welcome these inspiring entrepreneurs and help them accelerate their vision,” said RAMP director Lisa Garcia. “Not only